Health Care·Biotechnology·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.45 | N/A | +5.66% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.45 | N/A | +5.66% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautious optimism regarding their drug development pipeline. They emphasized the importance of their ongoing clinical trials, even without revenue guidance.
Management highlighted ongoing efforts in drug development.
They expressed confidence in their pipeline despite the lack of revenue.
Focus remains on advancing clinical trials.
Centessa Pharmaceuticals reported a narrower-than-expected loss per share, which was viewed positively by investors. However, the stock reaction remained flat, indicating that investors may be waiting for more concrete revenue figures or updates on their drug pipeline. The lack of revenue data and guidance may lead to uncertainty in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RIGETTI COMPUTING IN
Mar 27, 2023